1. The sensitivity and specificity of detecting the JAK2 p.V617F mutation in peripheral blood are both 100% compared to bone marrow.
Introduction
Somatic mutation of the JAK2 gene (JAK2 p.V617F) can be detected in a variable proportion of patients with myeloproliferative neoplasms (MPNs). 1 The JAK2 p.V617F mutation is observed in up to 96% of patients with polycythemia vera (PV) and approximately 55-65% of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF), and testing for its presence is an integral part of the diagnostic workup. 2 In addition, quantitative measurement of the JAK2 p.V617F allele burden (ratio of mutant allele to total allele) has been associated with certain clinical phenotypes, such as higher incidence of pruritus, splenomegaly, and increased risk of thrombosis in patients with PV and ET, although the exact association between allele burden and long-term outcome remains controversial, particularly in patients with MF. 
Patients and Methods
By retrospective chart review, we identified 388 patients with a diagnosis of MPN Genomic DNA was extracted from freshly obtained PB or BM aspirate samples using a semi-automated DNA-extraction method following the manufacturer's instructions (Gentra Autopure; Qiagen, Valencia, CA). The JAK2 p.V617F mutation was detected using PCR-based pyrosequencing, as previously described. 12 The sensitivity of detecting the JAK2 p.V617F mutation by this assay was 5%. Correlation between the JAK2 p.V617F allele burden measured in PB and BM was evaluated by scatter plot.
Linear regression was conducted to calculate coefficient of determination (R For
Results and Discussion
Among the 388 patients included in our analysis, 243 (63%) had a diagnosis of PMF, 48 (12%) had MF secondary to PV (post-PV MF), 38 (10%) had MF secondary to ET (post-ET MF), 32 (8%) had ET, and 27 (7%) had PV. Median time from diagnosis of MPN to JAK2 p.V617F testing was 5.9 months (range: 0-382 months) ( Table 1 ).
All patients who were negative for JAK2 p.V617F in PB samples were also negative in BM samples and vice versa, making the sensitivity and specificity of JAK2 p.V617F mutation detection in PB samples both 100% in the current MPN cohort (using BM testing as a reference).
Among patients who tested positive for JAK2 p.V617F, the median JAK2 p.V617F allele burden in PB and BM were 52.7% (range; 3.3-100) and 51.4% (range; 3.1-98.7), respectively, in all MPN patients (Table 1) . Patients with post-PV MF had the highest JAK2 p.V617F allele burden (median 92.6% in PB and 91.5% in BM), while patients with primary ET had the lowest (median 18.3% in PB and 18.9% in BM). The correlation between the JAK2 p.V617F allele burden measured in PB and BM samples in all MPN patients was very strong (R 2 =0.991; P<0.0001, Figure 1A ). The correlation remained strong for each MPN subtype (Figures 1B-D) .
In summary, our data from a large cohort of patients with MPN (MF, ET and PV) confirmed the consistency of detecting JAK2 p.V617F between PB and BM samples by the method used in our study. Moreover, our data confirmed that the JAK2 p.V617F allele burden measured in PB is equivalent to that measured in BM, which is in agreement with results from earlier published studies. 8, 10 These findings are valuable from a clinical perspective. Our results show that BM testing is not required to detect JAK2 p.V617F mutation or quantify JAK2 p.V617F allele burden because PB testing is highly reliable. Hence, a negative result of the JAK2 p.V617F mutation in a PB sample can be considered to be reliable, and obtaining a BM sample for further testing does not seem to be necessary. In the other words, our results dispel a notion that one needs to obtain a bone marrow aspirate and biopsy to be able to verify the presence or absence of the JAK2 p.V617F mutation. Further, our results strongly suggest that heterogeneity of sampling (PB vs. BM) can be essentially ignored when interpreting clinical correlation studies of JAK2 p.V617F allele burden. allele burden seems to function as minimal residual disease marker. 8, 13, 14 It should be noted, however, that the sensitivity of the assay used in the current study is 5%.
Because the presence of a very low level of residual JAK2 p.V617F allele burden can be clinically significant in a post-transplant setting, a future study to confirm the qualitative and quantitative accuracy between PB and BM samples using more sensitive assays is needed. A.
